AFP-L3

Immutable X Unveils Cross-Rollup Liquidity Solution on Ethereum with StarkNet, Supporting Planet-Scale Games with Multiple Layer 2 and Layer 3s

Retrieved on: 
Wednesday, May 25, 2022
L3, L1, GameStop, ESL, Environment, Multimedia, View, Non-fungible token, L2, Digital collectible card game, CTO, AFP-L3, Partnership, UX, TikTok, Blockchain, Immutable object, Ecosystem, Decentralized finance, NFT, Super-Pharm, CEO, Video game, Video game console, Cryptocurrency, Ethereum, Illuvium, High-rise building

SYDNEY, May 24, 2022 /PRNewswire/ -- Immutable X, which is powering the next generation of web3 games as the leading carbon-neutral, scalable platform for trading NFTs on Ethereum, today announced its expansion to be the world's first cross-rollup liquidity platform for NFTs, built on StarkNet. This announcement allows players to directly trade any asset matched across multiple Ethereum Layer 2 and Layer 3 roll-ups, solving the liquidity fractionalization problem that occurs with every individual roll-up today and scaling to billions of users. The protocol will facilitate hundreds of thousands of transactions per second, supporting games with hundreds of millions of daily players to truly own their in-game items.

Key Points: 
  • "This is the future of Ethereum - multiple roll-ups for different purposes and games, each abstracted and unified in liquidity via Immutable X - while never compromising on Ethereum's security," said Robbie Ferguson, Co-Founder at Immutable.
  • Ethereum remains the #1 choice for game developers, and Immutable X is focused on bringing the best games in the world to Ethereum.
  • World-class games have different needs, and therefore Immutable X will support multiple L2/L3 zk-rollups for different use cases.
  • "Our partnership will seamlessly enable world-class games and projects to thrive on Immutable X and StarkNet across L2 and L3."

Cardinal Health expands solutions to mitigate missed cancer screenings

Retrieved on: 
Monday, October 25, 2021
Cancer, Diagnosis, Blood, HCC, JAMA, Risk assessment, Pathology, Cardinal Health, Patient, Liver cancer, NYSE, Breast, AFP-L3, Risk, Colonoscopy, Collection, CAH, COVID-19, Awareness, Chronic liver disease, Solution, Death, Colon, DCP, Prostate cancer, Liver, Pharmaceutical industry, Medical imaging

"We're adding new testing solutions to our portfolio to reduce barriers to screening and support patient-led cancer screenings."

Key Points: 
  • "We're adding new testing solutions to our portfolio to reduce barriers to screening and support patient-led cancer screenings."
  • According to a report in JAMA Oncology 2, nearly 10 million cancer screenings for breast, colon and prostate cancer were missed in the U.S. since the pandemic began.
  • "A missed screening increases the likelihood of a late-stage cancer diagnosis, which is associated with poor prognosis," says Nicholas Sullivan, Ph.D., a senior product manager at Cardinal Health Laboratory Products with a background in cancer biology and clinical laboratory medicine.
  • "This high number of missed screenings during the pandemic has the potential to impact cancer patient outcomes for years."

Eureka Therapeutics Announces Initiation of Phase I/II ARYA-3 Clinical Trial of GPC3 Targeting ARTEMIS® T Cell Therapy in Liver Cancer

Retrieved on: 
Wednesday, July 21, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medical specialties, Clinical medicine, Cancer, Hepatology, Glypican 3, Hepatocellular carcinoma, Liver cancer, Ovarian cancer, Alpha-fetoprotein, Glypican, AFP-L3

Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the initiation of a Phase I/II clinical trial of ECT204, a GPC3 targeting ARTEMIS T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer.

Key Points: 
  • Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the initiation of a Phase I/II clinical trial of ECT204, a GPC3 targeting ARTEMIS T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer.
  • The GPC3 protein is also expressed in other solid tumors including ovarian and lung cancer.
  • With ET140203, the ARTEMIS receptor targets an alpha fetoprotein (AFP)-peptide/HLA-A2 complex found on liver cancer cells using a TCR-mimic antibody.
  • Eureka Therapeutics, Inc. is a privately held clinical-stage biotechnology company focused on developing novel T cell therapies to treat cancers.

Helio Health Announces China NMPA Acceptance of Registration Application for Helio Liver Test

Retrieved on: 
Wednesday, March 24, 2021
Medical specialties, Hepatology, Clinical medicine, Medicine, Tumor markers, Cancer, Hepatocellular carcinoma, Liver cancer, Alpha-fetoprotein, Circulating free DNA, AFP-L3, Liver tumor

IRVINE, Calif., March 24, 2021 /PRNewswire/ -- Helio Health , an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the China National Medical Products Administration (NMPA) has accepted the Company's registration application for its Helio Liver Test, a cell-free DNA (cfDNA) methylation blood test for the detection of hepatocellular carcinoma (HCC) or liver cancer.

Key Points: 
  • IRVINE, Calif., March 24, 2021 /PRNewswire/ -- Helio Health , an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the China National Medical Products Administration (NMPA) has accepted the Company's registration application for its Helio Liver Test, a cell-free DNA (cfDNA) methylation blood test for the detection of hepatocellular carcinoma (HCC) or liver cancer.
  • The study evaluated 1,093 individuals in China with HCC and benign liver diseases as well as healthy controls.
  • "We look forward to working with the Chinese regulatory authorities to advance registration of the Helio Liver Test in China and we plan to share the encouraging details of the VICTORY trial at a later date."
  • The Helio Liver Test was validated in an independent cohort of 631 subjects, including patients with HCC (n=291) and age-matched healthy controls (n=340), compared to serum alpha-fetoprotein (AFP) alone, a well-known marker for liver cancer.

Median Technologies: iBiopsy®: Promising Results on a Preliminary Study to Evaluate the Risk of Tumor Recurrence in Patients With Primary Liver Cancer

Retrieved on: 
Wednesday, June 17, 2020
Oncology, Health, Clinical trials, Research, Science, Biotechnology, Medicine, Medical specialties, Hepatology, Clinical medicine, Hepatocellular carcinoma, Liver cancer, Brachyury, Biomarker, AFP-L3, Fibrolamellar hepatocellular carcinoma

Median Technologies (Paris:ALMDT) (ALMDT), The Imaging Phenomics Company, announces today the results of a preliminary retrospective study on the evaluation of the risk of recurrence for patients with primary liver cancer (HCC hepatocellular carcinoma) based on a non-invasive biomarker.

Key Points: 
  • Median Technologies (Paris:ALMDT) (ALMDT), The Imaging Phenomics Company, announces today the results of a preliminary retrospective study on the evaluation of the risk of recurrence for patients with primary liver cancer (HCC hepatocellular carcinoma) based on a non-invasive biomarker.
  • The level of hepatic fibrosis1 is of great prognostic value and helps inform therapeutic intervention with regard to liver disease.
  • There was a two-fold objective for the preliminary retrospective study: first, to accurately quantify liver fibrosis on CT images, and second, to correlate the score of fibrosis with the risk of recurrence in post-operative patients with HCC.
  • Using this quantification methodology, iBiopsy non-invasive fibrosis biomarker permits the stratification of pre-operative patients at high-risk of tumor recurrence (HR = 4.1 (CI: [1.2,13.9], p-value